Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 936 trials

Leukemia and Lymphoma: Ruxolitinib and Venetoclax Study

We are studying the safety and effectiveness of ruxolitinib and venetoclax in children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. This research aims to find better treatment options for these young patients.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Hematological Cancers in Children: New Drug Combination Study

We are testing a combination of Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for children with relapsed or refractory hematological malignancies. The goal is to assess safety and see if it works for patients with specific genetic changes.

Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Chronic Lymphocytic Leukemia: Mosunetuzumab and Venetoclax Study

We are testing a new treatment combining Mosunetuzumab and Venetoclax for patients with relapsed or refractory chronic lymphocytic leukemia. The goal is to evaluate its safety and effectiveness compared to Mosunetuzumab alone.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Oncology

Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018

We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.

Fallopian Tube CancerPrimary Peritoneal CancerOvarian CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Ovarian Cancer: Niraparib and Abemaciclib Combination

We are studying the effects of combining niraparib and abemaciclib for patients with late-stage ovarian cancer. This trial aims to see if this treatment can improve outcomes for those who have already received other therapies.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

Multiple Myeloma: Belantamab Treatment Study

We are investigating the safety and effectiveness of belantamab for treating multiple myeloma, both on its own and with other therapies. This study aims to find out how well it works for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Acute Myeloid Leukemia: Hydroxyurea and Valproic Acid Study

We are investigating a new treatment combination for patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who cannot receive standard chemotherapy. The study will assess safety, effectiveness, and quality of life.

Acute Myeloid Leukemia6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Isolated MMA: Long-Term Study of mRNA-3705

We are evaluating the long-term safety and effects of mRNA-3705 in individuals with Isolated MMA who have participated in earlier studies. This research aims to understand how the treatment impacts health and daily activities over time.

Methylmalonic AciduriaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal Medicine

Hemophilia A: Dendritic Cell Therapy

We are testing a new treatment using patients' own dendritic cells to help manage severe bleeding in hemophilia A. This study aims to see if it can improve the body's tolerance to a crucial clotting factor.

Hemophilia A with Anti Factor VIII>2 yearsSafety phase (I)Hematology

Glioblastoma: [177Lu]Lu-NeoB Treatment Study

We are exploring a new radioactive treatment for patients with newly diagnosed glioblastoma, and testing it alone for those whose cancer has returned. The goal is to find the best dose and understand its effects.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Aggressive B-cell Non-Hodgkin Lymphomas: REGN5837 and Odronextamab

We are studying the safety of a new treatment combination for adults with aggressive B-cell non-Hodgkin lymphomas. This trial aims to see how well these medications work together.

B-cell Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)HematologyOncology

Multiple Myeloma: TG01/QS-21 Vaccine Study

We are investigating a new vaccine for patients with specific genetic mutations in multiple myeloma. The study aims to evaluate its safety and effectiveness in those at high risk or with measurable disease.

Multiple MyelomaSafety phase (I)Efficacy phase (II)HematologyOncology

Recurrent Prostate Cancer: SpectraCure P18 System Study

We are evaluating a new treatment system using lasers and a drug for men with recurrent prostate cancer. The study aims to ensure safety and effectiveness in targeting and eliminating cancer cells.

Recurrent Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Lymphoma Treatment: STP938

We are testing a new drug called STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas. The goal is to see if it can provide a new treatment option for those who have not responded to other therapies.

B-cell LymphomaT-cell Lymphoma>2 yearsSafety phase (I)HematologyOncology

B-cell Acute Lymphoblastic Leukemia: UCART22 Treatment Study

We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Cancer Treatment: HRO761 for Specific Genetic Changes

We are studying the effects of HRO761 in cancer patients with certain DNA alterations known as Microsatellite Instability-High or Mismatch Repair Deficiency. This trial will help us understand how well this treatment works alone and with other therapies.

Microsatellite Instability (MSI) and Mismatch Repair Cancer Syndrome>2 yearsSafety phase (I)Oncology

Advanced Cancers: KFA115 Treatment Study

We are exploring a new drug, KFA115, alone and with pembrolizumab for patients with advanced cancers. The goal is to understand its safety and how well it works.

Epithelial Ovarian CancerThymic CarcinomaMesothelioma1-2 yearsSafety phase (I)Oncology

Pelizaeus-Merzbacher Disease: ION356 Treatment Study

We are evaluating the safety of ION356, a new treatment for Pelizaeus-Merzbacher Disease. This study will help us understand how well the treatment is tolerated when administered directly into the spinal fluid.

Pelizaeus-Merzbacher DiseaseSafety phase (I)No PlaceboInvestigational MedicinesNeurology

Advanced Solid Tumors: INCA033890 Study

We are testing a new treatment called INCA033890 for individuals with advanced or metastatic solid tumors. This study aims to understand its safety and how it can be used in future treatments.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Advanced Breast Cancer: [177Lu]Lu-NeoB with Ribociclib and Fulvestrant

We are exploring a new treatment combination for patients with ER+, HER2-, and GRPR+ advanced breast cancer who have not responded to earlier therapies. The study aims to assess the safety and effectiveness of this approach.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)EndocrinologyOncology